GSK (LON:GSK) PT Lowered to GBX 1,900

GSK (LON:GSK) had its target price cut by equities researchers at Citigroup from GBX 2,120 ($26.82) to GBX 1,900 ($24.03) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s target price would suggest a potential upside of 24.75% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 ($24.66) price target on shares of GSK in a report on Friday, June 28th. Shore Capital restated a “buy” rating on shares of GSK in a report on Thursday, June 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 ($26.56) price target on shares of GSK in a research report on Thursday, June 27th. Barclays restated an “equal weight” rating and issued a GBX 1,725 ($21.82) price objective on shares of GSK in a report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,766.25 ($22.34).

GSK Stock Up 0.8 %

Shares of GSK stock opened at GBX 1,523 ($19.26) on Friday. The company has a debt-to-equity ratio of 134.34, a quick ratio of 0.73 and a current ratio of 0.87. GSK has a 52-week low of GBX 1,302.60 ($16.48) and a 52-week high of GBX 1,823.50 ($23.06). The company’s 50 day moving average price is GBX 1,675.37 and its 200-day moving average price is GBX 1,631.58. The stock has a market capitalization of £62.14 billion, a price-to-earnings ratio of 1,396.79, a P/E/G ratio of 1.19 and a beta of 0.27.

Insider Buying and Selling

In other GSK news, insider Wendy Becker bought 446 shares of the firm’s stock in a transaction on Thursday, June 20th. The stock was acquired at an average price of GBX 1,614 ($20.41) per share, with a total value of £7,198.44 ($9,105.03). 1.60% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.